CNS Pharmaceuticals, Inc. — Regulation A 1-A/A
CNS Pharmaceuticals, Inc. of HOUSTON, TX filed a Regulation A 1-A/A with the SEC on 2018-10-26. Aggregate offering: $17.3M (Tier 2). Industry: Other.
Offering
- Filed: 2018-10-26
- Form: 1-A/A
- Accession: 0001683168-18-003156
- Tier: Tier 2
- Total aggregate offering: $17.3M
- Issuer portion: $17.3M
- Price per security: $6.0000
- Securities offered: Equity (common or preferred stock), Security to be acquired upon exercise of option, warrant or other right to acquire security
- Underwriter: Boustead Securities, LLC
- Audit status: Audited
- Auditor: GBH CPAs, PC
- Jurisdictions: 102 states/territories
Issuer
- CIK: 0001729427
- Organized in: NV
- Incorporated: 2017
- Address: 2100 WEST LOOP SOUTH, HOUSTON, TX, 77027
- Phone: 800-946-9185
- Employees: 4 part-time
Financial snapshot (as filed)
- Total assets: $915K
- Cash & equivalents: $381K
- Total liabilities: $1.1M
- Stockholder equity: $-184K
- Net income: $-567K
People (1)
| Name | Role | Location |
|---|
| Matthew Lourie | Signer | The Woodlands, TX |
Other Reg A filings by this issuer (3)
More